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Background: Inhibition of KCa2 channels, conducting IKCa, can convert atrial fibrillation
(AF) to sinus rhythm and protect against its induction. IKCa inhibition has been shown to
possess functional atrial selectivity with minor effects on ventricles. Under
pathophysiological conditions with ventricular remodeling, however, inhibiting IKCa can
exhibit both proarrhythmic and antiarrhythmic ventricular effects. The aim of this study was
to evaluate the effects of the IKCa inhibitor AP14145, when given before or after the IKr
blocker dofetilide, on cardiac function and ventricular proarrhythmia markers in pigs with
or without left ventricular dysfunction (LVD).
Methods: Landrace pigs were randomized into an AF group (n = 6) and two control
groups: SHAM1 (n = 8) and SHAM2 (n = 4). AF pigs were atrially tachypaced (A-TP) for 43
± 4 days until sustained AF and LVD developed. A-TP and SHAM1 pigs received 20 mg/
kg AP14145 followed by 100 µg/kg dofetilide whereas SHAM2 pigs received the same
drugs in the opposite order. Proarrhythmic markers such as short-term variability of QT
(STVQT) and RR (STVRR) intervals, and the number of premature ventricular complexes
(PVCs) were measured at baseline and after administration of drugs. The influence on
cardiac function was assessed by measuring cardiac output, stroke volume, and relevant
echocardiographic parameters.
Results: IKCa inhibition by AP14145 did not increase STVQT or STVRR in any of the pigs. IKr
inhibition by dofetilide markedly increased STVQT in the A-TP pigs, but not in SHAM
operated pigs. Upon infusion of AP14145 the number of PVCs decreased or remained
unchanged both when AP14145 was infused after baseline and after dofetilide.
Conversely, the number of PVCs increased or remained unchanged upon dofetilide
infusion. Neither AP14145 nor dofetilide affected relevant echocardiographic parameters,
cardiac output, or stroke volume in any of the groups.
Conclusion: IKCa inhibition with AP14145 was not proarrhythmic in healthy pigs, or in the
presence of LVD resulting from A-TP. In pigs already challenged with 100 µg/kg dofetilide
there were no signs of proarrhythmia when 20 mg/kg AP14145 were infused. KCa2in.org May 2020 | Volume 11 | Article 5561
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Frontiers in Pharmacology | www.frochannel inhibition did not affect cardiac function, implying that KCa2 inhibitors can be
administered safely also in the presence of LV dysfunction.Keywords: ventricular dysfunction, KCa2 channels, small-conductance Ca2+-activated K+ channels, atrial fibrillation,
pig model, dofetilideINTRODUCTION
Heart failure and atrial fibrillation (AF) are present
concomitantly in many patients and can cause and exacerbate
each other through structural cardiac remodeling, activation of
neurohormonal mechanisms, and rate-related impairment of left
ventricular function.
Efficacy of class III antiarrhythmic drugs relies on the ability
to prolong the atrial effective refractory period (AERP).
Traditional class III drugs such as dofetilide are inhibitors of
the potassium current carried by the Kv11.1 protein, IKr. Since IKr
is present in the ventricles, inhibition of the current can delay
ventricular repolarization seen as an increased QT interval on the
surface electrocardiogram (ECG). Prolongation of the QT
interval corrected for heart rate (QTc) is associated with
increased risk of the potentially lethal ventricular arrhythmia
torsades de pointes (TdP) (Workman et al., 2011) and is
commonly used as a surrogate marker for proarrhythmicity.
However, QTc prolongation alone is an imperfect proarrhythmia
marker since not all drugs that prolong the QTc are
proarrhythmic (Piccini et al., 2009). Another surrogate marker
for proarrhythmicity that has been suggested to be superior to
QTc interval prolongation to predict TdP-risk is beat-to-beat
variability quantified by short-term variability of the QT interval
(Thomsen et al., 2004, Varkevisser et al., 2012).
The KCa2 channels, also known as small conductance Ca
2+-
activated K+, or small-conductance Ca2+-activated K+ (SK)
channels, conducting IKCa are a relatively novel target for AF
treatment. IKCa inhibition with different compounds can convert
AF to sinus rhythm and/or protected against its induction. This has
been shown in AF models in isolated perfused hearts from rat,
guinea pig, and rabbit as well as in in vivomodels in rats, dogs, pigs,
goats, and horses (Diness et al., 2010; Diness et al., 2011; Skibsbye
et al., 2011; Qi et al., 2013; Haugaard et al., 2015; Diness et al., 2017;
Gatta et al., 2019). IKCa inhibition has been shown to possess
functional atrial selectivity with minor effects on ventricles
(Diness et al., ; Diness et al., 2010; Qi et al., 2013; Skibsbye et al.,
2014; Kirchhoff et al., 2019).
Under certain pathophysiological conditions such as
myocardial infarction and congestive heart failure ventricular
KCa2 current can be increased. Blocking KCa2 currents under
such circumstances can exhibit both neutral (Lubberding et al.,
2019), proarrhythmic (Chang et al., 2013; Bonilla et al., 2014),
and antiarrhythmic (Chua et al., 2011; Gui et al., 2013; Hundahl
et al., 2017; Yin et al., 2017; Lubberding et al., 2019) ventricular
effects, depending on the experimental setup.
We hypothesized that inhibiting KCa2 channels would
increase ventricular proarrhythmia markers in pigs with
ventricular structural remodeling and dysfunction while pigs
without structural remodeling will not be affected. The aim ofntiersin.org 2this study was to evaluate the effects of the KCa2 channel
inhibitor AP14145, when given before or after the Kv11.1
channel blocker dofetilide, on cardiac function and ventricular
proarrhythmia markers in pigs with or without atrial and
ventricular structural remodeling and dysfunction.MATERIALS AND METHODS
Experimental Animals
All animal studies were performed under a license from the
Danish Ministry of Environment and Food (license No. 2014-15-
0201-00390), in accordance with the Danish guidelines for
animal experiments according to the European Commission
Directive 86/609/EEC. A total of 18 female Danish landrace
pigs were included in the study. The pigs were 11 weeks old on
the day of arrival and weighed 25–35 kg. The pigs were
randomized into two groups: long-term atrially tachypaced (A-
TP) pigs with AF and sham operated control (SHAM) pigs. The
A-TP pigs were tachypaced until AF that was resistant to
cardioversion by 4 mg/kg vernakalant (18 ± 2 days of A-TP) as
previously described (Diness et al., 2017) and then for
additionally 25 ± 4 days for a total of 43 ± 4 days of A-TP. All
pigs were treated with a daily dose of 250 µg digoxin in order to
prevent clinical signs of heart failure, but developed some degree
of left ventricular dysfunction as described previously (Citerni
et al., 2020). The surgical procedure for pacemaker implantation
and post-operative treatments were previously described
(Diness et al., 2017).
All pigs underwent a terminal experiment in which the effects
of KCa2 channel inhibition by AP14145 and Kv11.1 channel
inhibition with dofetilide on cardiac output (CO) and different
echocardiographic and electrophysiological parameters were
tested. The timelines of the terminal experiments with A-TP,
SHAM1, and SHAM2 pigs can be observed in Figure 1. The pigs
were divided as follows: 12 control animals (4 SHAM1 and 8
SHAM2 pigs) and 6 A-TP. One of the A-TP pigs was excluded
from CO and stroke volume (SV) statistical analyses due to
spontaneous conversion to sinus rhythm (SR) upon induction
of anesthesia.
After premedication with Zoletil pig mixture (see
Supplementary Materials for details), pigs were anesthetized
with intravenous propofol and fentanyl (15 mg/kg/h and 5 µg/
kg/h, respectively) and intubated and ventilated with a tidal
volume of 10 ml/kg and a respiration frequency of 12–14/min.
During surgery partial pressure of carbon dioxide (PaCO2),
blood pressure and ECG were monitored and the pig was
given 6 ml/kg/h isotonic salt solution. CO was measured by
thermodilution method via a Swan-Ganz catheter placed into theMay 2020 | Volume 11 | Article 556
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The external mammary vein was catheterized for drug infusion.
Drugs
In the present study, A-TP pigs received a 1-h infusion of 20 mg/
kg AP14145 60 min after electrical cardioversion. Ten minutes
after the end of AP14145 infusion, 0.1 mg/kg dofetilide was
infused over 15 min. SHAM1 pigs followed the same infusion
protocol as the A-TP pigs. SHAM2 pigs received dofetilide 60
min after induction of anesthesia followed by AP14145 30 min
after the end of dofetilide injection. The longer break between the
infusions in the SHAM2 pigs was necessary to allow
echocardiographic assessment after dofetilide infusion.
Electrophysiological Assessment of
Proarrhythmia Risk
Drug-induced prolongation of the QTc interval is often
considered an important safety variable, and if excessive it may
be a predictor of TdP (Belardinelli et al., 2003). However, QTc
prolongation alone is an imperfect proarrhythmia marker since
drugs that prolong the QTc interval to the same extent do not
necessarily carry the same risk of proarrhythmia (Belardinelli
et al., 2003; Piccini et al., 2009). The beat-to-beat variability of
repolarization is quantified by short-term variability (STV). STV
of QT intervals (STVQT) has been suggested to be superior to
QTc prolongation in predicting drug-induced TdP risk of
various cardiovascular drugs in certain experimental assays
(Thomsen et al., 2004; Detre et al., 2005). In this study changes
in both the QTc (corrected for heart rate with Bazett’s formula)
and STVQT were analyzed to assess the risk of ventricular
proarrhythmia. Pigs were equipped with three bipolar standard
ECG leads. The ECGs analyzes was carried out semi-Frontiers in Pharmacology | www.frontiersin.org 3automatically with manual adjudication in LabChart. The
STVQT, the STV of RR intervals (STVRR), and QTc were
calculated from 30 consecutive beats just before and at the end
of each compound infusion using the following formula: STV=
∑|Dn+1–Dn|/[30*√2], where D represents the duration of RR or
QT and 30 is the number of consecutive beats chosen for the
measurement (Thomsen et al., 2004).
In this study, premature ventricular complexes (PVCs) were
calculated by manual adjudication from bipolar standards leads
over a 15-min period just before (baseline) as well as immediately
after infusion of AP14145 and dofetilide, respectively.
Assessment of Cardiac Function
Echocardiography
Echocardiography was performed before and during the last 15
min of AP14145 infusion in order to examine effects on inotropy
and other parameters for cardiac function (Figure 1). In SHAM2
pigs, echocardiograms were also obtained after infusion of
dofetilide. A standardized transthoracic echocardiographic
examination (TTE) together with the newly introduced trans-
diaphragmatic echocardiographic (TDE) approach (Citerni
et al.,) with the pig in dorsal recumbency using right
parasternal and left apical windows was performed and
digitally stored using an Philips iE33 machine (Philips
Healthcare, Amsterdam, the Netherlands) equipped with a S5-
1 transducer (3.5 MHz) and continuous electrocardiographic
(ECG) monitoring. Offline echocardiographic analysis was
performed using EchoPAC version 113 with the observer
blinded to the identity of the recording. All reported values are
averages of three consecutive heart cycles during sinus rhythm.
Left ventricular (LV) function was assessed as LV ejection
fraction (LVEF) with the four chamber modified Simpson’sFIGURE 1 | Timelines for the atrially tachypaced (A-TP), SHAM1, and SHAM2 groups. DC, direct current cardioversion; CO, cardiac output measurement; Echo,
echocardiography; AP14145, a dose of 20 mg/kg AP14145 infused over 60 min; Dofetilide, a dose of 0.1 mg/kg dofetilide infused over 15 min.May 2020 | Volume 11 | Article 556
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the ratio between maximum diastolic and systolic LV internal
areas measured in short axis (SAX) (Thomas et al., 1993; Ravn
et al., 2014). Left atrial (LA) volume was evaluated with the
biplane modified Simpson’s method of disks (Lang et al., 2015),
using the four chamber view (van den Dorpel et al., 2018).
Furthermore LV diastolic function was assessed by mitral
valve inflow Doppler patterns [transmitral E/A ratio and E
velocity deceleration time (EDT)] and pulse wave tissue
Doppler imaging (E’ septal and E/E’ ratio) (van den Dorpel
et al., 2018). Peak aorta flow velocity was estimate using pulse
wave Doppler imaging (Ravn et al., 2014).
Estimation of Cardiac Output and Stroke Volume
CO and SV were measured by thermo dilution via the Swan-
Ganz catheter using a rapid injection of 10 ml of saline (0.9%)
injection at 4°C into the pulmonary artery via the jugular vein.
The CO was calculated as an average of three consecutive
measurements in a row at four times points for the A-TP and
at 3 time points for the SHAM pigs: immediately before ECV in
AF only for A-TP; 1 h after ECV in SR just before AP14145
infusion for A-TP and 1 h after anesthesia for SHAM;
immediately after AP14145 and dofetilide infusions (Figure 1).
SV was calculated dividing the CO with the HR.
Statistical Analyses
GraphPad Prism 8 and LabChart 7 were used for data analysis
and figures.
STVQT and STVRR data were analyzed as follows: outliers
were removed with the ROUT (1%) test. Repeated measures
analyses were made with ANOVA if there were no missing
values and with mixed effects model in the case of missing values
(e.g., due to removal of outliers). Differences between STVQT and
STVRR between start and end of infusion of either AP14145 or
dofetilide were then compared using Sidak’s adjustment for
multiple comparisons. QTcB (The QT interval corrected for
heart rate with Bazett's formula) and RR interval data were
analyzed in the same way. The number of PVCs was analyzed
with a Friedman test followed by Dunn’s multiple comparisons
test using the number of PVCs after the first infusion of test
compound as the control. Cardiac output (CO) and stroke
volume (SV) data were analyzed as follows: repeated measures
analyses were made with ANOVA. The CO and SV data were
analyzed with one-way ANOVA followed by Sidak’s multiple
comparisons test using the data after the first infusion of test
compound as the control.
All echocardiographic data were tested for normality with
D’Agostino-Pearson test. Data that followed a Gaussian
distribution were analyzed with Student T-test, and the rest of
the data were tested with the Wilcoxon signed-rank test. Outliers
were removed with the ROUT (1%) test. Wilcoxon signed rank
test was used to compare echocardiographic data before and after
KCa2 channel inhibition in the SHAM1 pigs. In the SHAM2 pigs,
one-way ANOVA was used.
Data are summarized using the mean ± SEM. P-values are
given with three decimals and considered statistically significant
if <0.05.Frontiers in Pharmacology | www.frontiersin.org 4RESULTS
At the time of the pacemaker implantation, the pigs had an
average body weight of 31 ± 1 and 32 ± 1 kg for A-TP and
SHAM, respectively. At follow-up after 43 ± 4 days of A-TP the
weight had increased to 71 ± 4 and 69 ± 4 kg, respectively. No
significant difference in body weight between the groups was
observed at any point.
Substrate Development
The heart rate (HR) of the A-TP pigs was 130 ± 14 bpm during
AF, which upon electrical cardioversion (ECV) decreased to 71 ±
3 bpm which was similar to the HR of SHAM pigs at follow up
after 43 ± 4 days of A-TP (74 ± 4 bpm). The A-TP pigs had LV
and LA dysfunction and structural remodeling characterized by
increased abundance of extracellular matrix (ECM) and enlarged
LV and LA with reduced contractility compared the
SHAM controls.
After 43 ± 4 days of A-TP, A-TP pigs had developed reduced
myocardial contractility documented by LV systolic dysfunction
with reduced LVEF and FAC. Among diastolic function
parameters, LA volume was found increased, E/A was
increased by 50%, and peak A decreased by 21% even though
non-significantly, as well as five out of six pigs developed mild
mitral valve regurgitation compared to control. Furthermore, A-
TP pigs showed structural remodeling characterized by increased
abundance of extracellular matrix (ECM) in all cardiac
chambers. By contrast, all the echocardiographic parameters
and histological analyses were within normality in all SHAM
pigs as previously documented (Citerni et al., ).
Effects on STVQT and STVRR
The STVQT and STVRR values before and after infusion of
AP14145 and dofetilide are given in Table 1 and Figure 2.
KCa2 channel inhibition by AP14145 did not increase STVQT or
STVRR from baseline values in A-TP and SHAM1 pigs. The same
was the case when AP14145 was applied in the presence of
dofetilide in the SHAM2 pigs. On the contrary, a small and not
statistically significant decrease of STVQT after AP14145
administration could be observed in all groups of pigs.
Kv11.1 inhibition by dofetilide markedly increased STVQT in
the A-TP pigs and, to a lesser and not statistically significant
extent, in both groups of SHAM operated pigs.
A-TP and SHAM1 pigs received AP14145 followed by
dofetilide with a 10 min interval. In the SHAM2 group the
pigs received dofetilide first, and AP14145 afterwards with a 30
min interval. Repeated measures analyses were made with
ANOVA for all groups except for the SHAM2 group where a
mixed model analysis was applied due to removal of two outlier
values. Differences between STVQT and STVRR between start and
end of infusion of either AP14145 or dofetilide were compared
using Sidak’s adjustment for multiple comparisons.
Effects on QTcB and Heart Rate
The QTcB and RR interval values before and after infusion of
AP14145 an dofetilide are given in Table 2 and Figure 3. The
QTcB was not increased significantly by AP14145 in any of theMay 2020 | Volume 11 | Article 556
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in RR intervals) in all three groups, although only to a
statistically significant extent in the SHAM1 group.
Conversely, dofetilide decreased the heart rate in all groups
of pigs, but only to a statistically significant extent in the A-TP
group. As expected, dofetilide increased the QTcB in allFrontiers in Pharmacology | www.frontiersin.org 5groups of pigs, although only to a statistically significant
extent in the SHAM2 group.
A-TP and SHAM1 pigs received AP14145 followed by
dofetilide. In the SHAM2 group the pigs received dofetilide
first, and AP14145 afterwards. Repeated measures analyses
were made with ANOVA for all groups. Differences betweenTABLE 1 | STVQT and STVRR expressed in milliseconds (ms) before and after infusion of AP14145 and dofetilide.
Group Parameter Start AP14145 End AP14145 Adjusted p-value Start dofetilide End dofetilide Adjusted p-value
ATP STVQT 3.2 ± 0.5 2.6 ± 0.7 0.810 2.2 ± 0.6 17.7 ± 5.2 0.045
STVRR 6.2 ± 1.7 1.8 ± 0.4 0.093 2.3 ± 0.5 17.7 ± 5.2 0.081
SHAM1 STVQT 2.6 ± 0.6 1.4 ± 0.2 0.136 2.2 ± 0.3 4.2 ± 1.6 0.544
STVRR 10.5 ± 2.1 6.7 ± 2.7 0.275 7.2 ± 2.3 38.2 ± 10.5 0.177
SHAM2 STVQT 3.0 ± 0.8 2.1 ± 0.2 0.328 4.6 ± 0.9 7.7 ± 3.2 0.747
STVRR 3.1 ± 0.9 2.1 ± 3.2 0.607 4.6 ± 0.8 7.7 ± 0.2 0.432May 2020 | VolumA C
B D
FIGURE 2 | STVQT and STVRR before and after infusion of AP14145 and dofetilide. Left column (A, B): STVQT+RR from the atrially tachypaced (A-TP) pigs and the
SHAM1 pigs. Right column (C, D): STVQT+RR from the SHAM2 pigs. Two outlier values were removed from the SHAM2 STVRR group.TABLE 2 | QTcB and RR intervals (in ms) before and after infusion of AP14145 and dofetilide.
Group Parameter Start AP14145 End AP14145 Adjusted p-value Start dofetilide End dofetilide Adjusted p-value
A-TP QTcB 285 ± 13 300 ± 16 0.327 301 ± 16 393 ± 47 0.115
RR 863 ± 35 709 ± 36 0.095 729 ± 37 879 ± 50 0.001
SHAM1 QTcB 305 ± 9 301 ± 10 0.799 302 ± 7 321 ± 11 0.113
RR 909 ± 50 795 ± 34 0.045 811 ± 35 919 ± 42 0.073
SHAM2 QTcB 372 + 22 359 + 33 0.694 334 ± 24 372 ± 23 <0.001
RR 795 + 59 707 + 57 0.325 776 ± 65 816 ± 51 0.373e 11 | Article 556
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compared using Sidak’s adjustment for multiple comparisons.
Effects on the Number of Premature
Ventricular Complexes
Upon infusion of AP14145 the number of PVCs decreased or
remained unchanged both when AP14145 was infused after
baseline and after dofetilide (Figure 4). Conversely, the
number of PVCs increased or remained unchanged upon
dofetilide infusion both when it was infused after baselineFrontiers in Pharmacology | www.frontiersin.org 6and after AP14145. However, none of these changes were
statistically significant.
Effects of KCa2 and Kv11.1 Inhibition on
Impaired and Normal Cardiac Function
In the A-TP pigs with impaired cardiac function as well as in the
healthy SHAM1 pigs neither KCa2 nor Kv11.1 inhibition exerted
significant effect on echocardiographic variables when AP14145
was given before dofetilide during the terminal experiment
(Table 3).FIGURE 4 | The number of premature ventricular complexes (PVCs) during the 15 min preceding the first infusion of test compound and after the end of AP14145
and dofetilide infusions, respectively. Left: the atrially tachypaced (A-TP) group. Middle: the SHAM1 group. Right: the SHAM2 group. The percentages of PVCs out of
the total number of heartbeats within each period are also given in the graphs. Data were analyzed with a Friedman test followed by Dunn’s multiple comparisons
test using the number of PVCs after the first infusion of test compound as the control. The adjusted p-values in the graphs are from Dunn’s test.A
B
C
D
FIGURE 3 | QTcB and RR intervals. Left column (A, B): QTcB and RR intervals from the atrially tachypaced (A-TP) pigs and the SHAM1 pigs. Right column (C, D):
QTcB and RR intervals from the SHAM2 pigs.May 2020 | Volume 11 | Article 556
Citerni et al. KCa2-Channel Inhibition in LVD PigsIn the healthy SHAM2 pigs, Kv11.1 inhibition by dofetilide
did not impact echocardiographic parameters when given before
AP14145. On the other hand, KCa2 inhibition by AP14145 did
lower the peak aorta velocity (1.4 ± 0.1 vs. 1.0 ± 0.1 m/s, P=0.045)
compared to dofetilide and increased the E/E’ septal ratio (7.6 ±
0.5 vs. 11 ± 0.3, P=0.040) when AP14145 was applied after
dofetilide (Table 4).
CO was recorded during SR 1 h after electrical cardioversion
for A-TP and 1 h after anesthesia for SHAM, and again
immediately after AP14145 and dofetilide infusions (Figure 1).
Neither AP14145 nor dofetilide affected CO or SV in any of the
groups (Figure 5).DISCUSSION
In the present study we evaluated the effects of the KCa2 channel
inhibitor AP14145, when given before or after the Kv11.1
channel blocker dofetilide, on cardiac function and ventricular
proarrhythmia markers in pigs with or without atrial and
ventricular structural remodeling and dysfunction. KCa2Frontiers in Pharmacology | www.frontiersin.org 7channel inhibition by AP14145 neither showed any signs of
ventricular proarrhythmia nor did it negatively affect
cardiac function.
Previous Studies With AP14145
Previously, four studies including AP14145 have been published
(Diness et al., 2017; Simó-Vicens et al., 2017; Kirchhoff et al.,
2019; Lubberding et al., 2019). In 2017, our group published the
first study describing how AP14145 acts as a negative allosteric
modulator of the KCa2 channel by right-shifting the curve of
activation by calcium (Simó-Vicens et al., 2017). Also, in 2017 we
published another study describing how AP14145 in vitro is
selective for KCa2 channels compared to other relevant cardiac
ion channels (Diness et al., 2017). In the same study, we
demonstrated that in vivo in pigs, AP14145 had functional
selectivity for atria versus ventricles and that it converted AF
that was resistant to treatment with vernakalant to sinus rhythm.
In 2019, we published a study showing that KCa2 channel
inhibition by AP14145 was functionally atrial selective
compared with Kv11.1 inhibition by dofeti l ide and
ondansetron which was functionally selective for ventriclesTABLE 4 | Measurements of systolic and diastolic myocardial function before and after infusion of 0.1 mg/kg of dofetilide over 15 min, and after infusion of 20 mg/kg
AP14145 over 60 min.
SHAM2 before dofetilide SHAM2 after dofetilide P value SHAM2 after AP14145 P value
Ejection fraction; EF (%) 69 ± 37 69 ± 37 0.989 66 ± 27 0.526
Fractional area change; FAC (%) 63 ± 25 57 ± 25 0.152 51 ± 25 0.126
Peak aortic flow velocity; (m/s) 1.4 ± 0.17 1.4 ± 0.17 0.970 1.0 ± 0.17 0.045
Peak E (m/s) 0.75 ± 0.083 0.78 ± 0.033 0.845 0.70 ± 0.083 0.403
Peak A (m/s) * 0.65 ± 0.10 3 0.75 ± 0.043 >0.999 0.79 ± 0.063 >0.999
EDT (ms) * 139 ± 243 144 ± 63 >0.999 142 ± 193 0.828
E/A * 1.2 ± 0.33 1.1 ± 0.13 >0.999 0.9 ± 0.13 0.205
E’ septal (m/s) 0.08 ± 0.01 0.09 ± 0.01 0.447 0.07 ± 0.01 0.258
E/E’ septal 11 ± 13 7.6 ± 13 0.278 11 ± 13 0.040
LA end-diastolic Vol. (ml) 29 ± 27 28 ± 17 0.889 26 ± 27 0.499
LA end-systolic Vol. (ml) 12 ± 17 12 ± 17 0.999 9 ± 17 0.073May 2020 | Volume 11 | ArValues are expressed in mean ± SEM. Superscripts are the number of animals from which the median in question has been calculated in case of missing observations. Values are
expressed in mean ± SEM. *Friedman test was performed for these parameters. Parameters were compared as follows: before vs. after administration of dofetilide and after dofetilide vs.
after AP14145.TABLE 3 | Measurements of systolic and diastolic myocardial functions.
SHAM1
Baseline
SHAM1
AP14145
P value A-TP
Baseline
A-TP
AP14145
P value
Ejection fraction; EF (%) 66 ± 3 66 ± 3 >0.999 49 ± 58 44 ± 38 0.392
Fractional area change; FAC (%) 66 ± 4 59 ± 9 0.625 40 ± 46 37 ± 36 0.552
Peak aortic flow velocity; (m/s) 1.3 ± 0.1 1.2 ± 0.1 0.625 1.1 ± 0.18 1.0 ± 0.18 0.244
Peak E (m/s) 0.68 ± 0.03 0.58 ± 0.02 0.125 0.63 ± 0.057 0.54 ± 0.037 0.117
Peak A (m/s) 0.60 ± 0.06 0.78 ± 0.05 0.125 0.50 ± 0.067 0.55 ± 0.077 0.297
EDT (ms) 206 ± 22 192 ± 15 0.625 152 ± 67 170 ± 157 0.121
E/A 1.17 ± 0.13 0.76 ± 0.03 0.125 1.40 ± 0.267 1.10 ± 0.127 0.159
E’ septal (m/s)* 0.10 ± 0.01 0.09 ± 0.01 0.250 0.08 ± 0.018 0.07 ± 0.018 0.504
E/E’ septal 6.7 ± 0.4 7.1 ± 0.7 0.625 8.4 ± 0.67 9.2 ± 1.57 0.691
LA end-diastolic Vol. (ml) 28 ± 3 24 ± 1 0.625 54 ± 87 58 ± 77 0.718
LA end-systolic Vol. (ml) 11 ± 1 8 ± 1 0.625 38 ± 77 35 ± 57 0.718Changes from before to after infusion of the KCa2 inhibitor AP14145 in the A-TP and SHAM l groups. All pigs were in sinus rhythm. Volumes of LA and LV measured with SMODmethod in
left apical 4 chamber view; LV area in systole and diastole measured in SAX view using 2D echocardiography to calculate fractional area change (FAC). Peak aorta flow velocity was
estimated using pulse wave Doppler imaging. MV Peak E, early diastolic velocity; MV Peak A, atrial contraction velocity; EDT, transmitral flow deceleration time; E/A, peak E and A ratio; E'
septal, isovolumic relaxation time; E/E', peak E and isovolumic relaxation time ratio. Superscripts are the number of animals from which the median in question has been calculated in case
of missing observations. Values are expressed in mean ± SEM. P values are expressed in the right columns (paired Student t-test for the A-TP pigs and Wilcoxon test for the SHAM1 pigs).
*E' lateral was not possible to measure at the baseline, therefore this parameter has been excluded from the analysis.ticle 556
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collaboration with ours, found that inhibition of KCa2 channels
with AP14145 was neither beneficial nor detrimental to
ventricular arrhythmia development in a porcine model of
acute myocardial infarction (Lubberding et al., 2019).
AP14145 and Dofetilide Doses
In previous experiments with AP14145 conversion of
vernakalant-resistant AF occurred already at a dose level of 5
mg/kg and thus an infusion of 20 mg/kg as was used in the
current study would be expected to give exposure well-above a
level that would be relevant for conversion of AF (Diness et al.,
2017). A relatively high dose of dofetilide, 0.1 mg/kg was used as
a positive control for increasing proarrhythmia markers.
In the clinic, cardioversion of AF is usually attempted with ~10
(4–12) µg/kg of dofetilide and thus a ten-fold higher dose was
expected to be proarrhythmic (Sedgwick et al., 1995; Falk et al.,
1997; Nørgaard et al., 1999; Lindeboom et al., 2000).
Effects of KCa2 Channel Inhibition on
Ventricular Electrophysiology
The effects of KCa2 channel inhibition with AP14145 on
ventricular electrophysiology were neutral or slightly
antiarrhythmic, seen as a small and not statistically significant
decrease of the STVQT in all groups of pigs as well as an
unchanged or decreased number of PVCs upon infusion of
AP14145. The QTcB was not affected to any significant extent
after AP14145 infusion in any of the pigs, similar to what has
previously been reported in pigs (Diness et al., 2017). These
effects of AP14145 on arrhythmia markers were the same in the
presence of the Kv11.1 inhibitor dofetilide as seen in the SHAM2
group: STVQT, QTcB, and the number of PVCs were all slightly
decreased, but not to any statistically significant extent.
In contrast, the Kv11.1 inhibitor dofetilide prolonged the
QTcB and increased STVQT in all groups of pigs (although the
QTcB increase was only statistically significant in the SHAM2Frontiers in Pharmacology | www.frontiersin.org 8pigs and the STVQT increase was only statistically significant in
the ATP pigs). The effects of dofetilide were comparable between
the two SHAM groups where STV QT and QTcB were increased
to similar extents. Regarding the number of PVCs, it seemed that
dofetilide alone increased the number of PVCs as seen in the
SHAM2 group, whereas this was not the case in the SHAM1
group where AP14145 was present. In the A-TP pigs dofetilide
seemed even more proarrhythmic; STVQT, QTcB, and the
number of PVCs was increased markedly more than in either
of the SHAM groups.
Based on our experiments we cannot conclude if AP14145
affected the proarrhythmic effect of dofetilide in A-TP pigs.
However, suffice it to say, that there was no indication of an
increase in any arrhythmia markers after the infusion of
AP14145 in any of the groups. On the contrary, the effect of
infusion of AP14145 on any of the measured proarrhythmia
markers was neutral at worst.
STVQT as a Predictor of Torsades de
Pointes
Hinterseer et al. conducted descriptive human studies
demonstrating that STVQT was approximately doubled in
individuals at risk for repolarization-dependent arrhythmias
compared to matched controls. This was the case in patients
known to be at risk for drug-induced TdP (Hinterseer et al.,
2008), patients with inherited long QT syndrome (LQTS)
(Hinterseer et al., 2009), and in patients with documented
non-ischaemic congestive heart failure (Hinterseer et al., 2010).
In dogs with chronic atrio-ventricular block (CAVB), the
STVQT and the STV of left ventricular monophasic action
potential duration (STVLV) is superior to the QT interval in
assessing the risk of drugs causing TdP (Varkevisser et al., 2012).
In a study by Dunnink et al. the STVLV increased from 1.4 ± 0.6
to 3.2 ± 1.6 ms and TdP occurred in 56% of the dogs after
treatment with 25 µg/kg dofetilide (Dunnink et al., 2012). Similar
a study by Thomsen et al. found that 25 µg/kg dofetilideA B C
D E F
FIGURE 5 | Top: cardiac output (CO) at baseline [60 min after cardioversion in the atrially tachypaced (A-TP) pigs] and immediately after infusion of each compound
in the A-TP (A), the SHAM1 (B), and SHAM2 (C) groups. Bottom: stroke volume (SV) at baseline and immediately after infusion of each compound in the A-TP (D),
the SHAM1 (E), and SHAM2 (F) groups. Repeated measures analyses were made with ANOVA in all groups. The data after the first infusion of test compound were
used as the control.May 2020 | Volume 11 | Article 556
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occurred in 74% of the dogs (Thomsen et al., 2007).
The changes we observed in STVQT after infusion of 100
µg/kg dofetilide in the SHAM pigs are of the same magnitude
as were observed in the CAVB dogs in the two studies by
Dunnink et al. and Thomsen et al. Interestingly, the increase
observed in the A-TP pigs in our study (from 2.2 ± 0.6 to
17.7 ± 5.2 ms) is, to the best of our knowledge, much larger
than any increase in STVLV or STVQT leading to TdP in the
CAVB dog model after testing “unsafe” drugs such as
sertindole, dofetilide, bepridil, terfenadine, and sotalol
(Varkevisser et al., 2012). However, no single episode of
TdP was observed in any of the pigs.
It therefore seems that pigs, even pigs with remodeled
ventricles and very increased STVQT, are less susceptible to
TdP than CAVB dogs. However, STVQT might still be a
valuable marker of proarrhythmia in pigs since it is increased
after dofetilide infusion. The fact that STVQT is increased to a
greater extent by dofetilide in the A-TP pigs than in the SHAM
pigs hints at a reduced repolarization reserve in the A-TP pigs.
Effects on the RR Interval and the STVRR
In the SHAM1 pigs the RR interval decreases during AP14145
treatment and returns to baseline values during dofetilide
infusion. The pattern is the same in the SHAM2 pigs: during
dofeti l ide infusion the RR increases (although less
pronounced than in the SHAM1 pigs) and decreases to
values below baseline afterwards during AP14145 infusion.
These observations fit very well with the half-lives of the
drugs: the most-reported half-life in the literature is 10 h for
dofetilide and the half-life of AP14145 has been reported to be
very short—only 24 min (Diness et al., 2017; Ibrahim and
Tivakaran, 2020). Thus, in the SHAM1 pigs during dofetilide
infusion the decreasing effects of AP14145 on the RR interval
are rapidly wearing off and this in combination with the effects
of dofetilide gives an increased variability in the RR interval,
and thus a rather steep rise in STVRR.
If the combination of AP14145 and dofetilide should
generally increase STVRR, we would expect this to give an even
more pronounced effect in the SHAM2 pigs at the end of
AP14145 infusion where the plasma concentration of both
compounds is high.
Effects on Cardiac Function
The echocardiographic examination at the terminal experiment
revealed that neither dofetilide nor AP14145 further worsened
the already impaired cardiac function in the A-TP. Dofetilide
and AP14145 also did not negatively affect normal cardiac
function in the SHAM pigs.
Despite the higher E/E’ septal ratio after AP14145 compared
to dofetilide in the SHAM2 pigs, both parameters values after
AP14145 were in line with the baseline values before dofetilide
infusion. Therefore, we do not think that these findings are of
clinical importance.
The peak aortic velocity was unaffected by AP14145 when
given alone in the SHAM1 and A-TP pigs. Similarly, the peak
aortic velocity was unaffected by dofetilide when given alone inFrontiers in Pharmacology | www.frontiersin.org 9the SHAM2 pigs. When AP14145 was administered after
dofetilide in the SHAM2 pigs the peak aortic velocity was
slightly lower. This finding is probably of very limited clinical
importance since it is within normal ranges for peak
aortic velocity.
In line with the echocardiographic examination, the results
from the measurements of the CO and SV demonstrated that
neither dofetilide nor AP14145 affected any of these parameters.LIMITATIONS
This study was only powered to detect relatively large and
uniform changes. Due to the relatively large variation in some
of the parameters that were tested changes that could have been
clinically relevant were not found to be statistically significant.
Nevertheless, the data obtained sufficed to obtain meaningful
insight into whether KCa2 channel inhibition with AP14145 was
proarrhythmic in a setting of LV dysfunction resulting from A-
TP or after challenging SHAM pigs with infusion of a high
dose dofetilide.CONCLUSION
KCa2 channel inhibition with AP14145 was not proarrhythmic in
healthy pigs, or in the presence of LV dysfunction resulting from
A-TP. Also, when 20 mg/kg AP14145 were infused in pigs
already challenged with 100 µg/kg dofetilide there were no
signs of proarrhythmia. On the contrary, after AP14145
infusion the number of PVCs as well as the QTc and the
STVQT were all slightly decreased, although not to an extent
that was statistically significant. Furthermore, KCa2 channel
inhibition did not affect cardiac function. This implies that
KCa2 inhibitors can be administered safely also in the presence
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